Related Experiment Video

Updated: May 31, 2026

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

Genetic studies of the protein kinase AKT1 in Parkinson's disease

Caroline Ran1, Marie Westerlund, Anna Anvret

  • 1Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.

Neuroscience Letters
|July 12, 2011
PubMed

Insights

Genetic variants in AKT1 (a protein kinase) are not associated with Parkinson's disease protection. A Swedish study found no link between AKT1 gene variations and the disease, contradicting earlier findings.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • The AKT1 gene encodes a protein kinase crucial for cell growth and survival.
  • Reduced AKT1 phosphorylation is observed in Parkinson's disease (PD) dopaminergic cells, suggesting a potential role in cell survival.
  • Previous studies indicated AKT1 involvement in dopaminergic system disorders and suggested a protective haplotype in Greek PD patients.

Purpose of the Study:

  • To replicate a previous study investigating the association between AKT1 genetic variants and Parkinson's disease.
  • To determine if specific AKT1 single nucleotide polymorphisms (SNPs) or haplotypes confer protection against Parkinson's disease in a Swedish cohort.

Main Methods:

  • Genotyping of four specific AKT1 SNPs (rs2494743, rs2498788, rs2494746, rs1130214).
  • Analysis of a Swedish case-control cohort comprising 243 Parkinson's disease patients and 315 controls.
  • Statistical analysis to assess the association between individual SNPs, haplotypes, and Parkinson's disease.

Main Results:

  • No statistically significant association was found between the genotyped AKT1 SNPs and Parkinson's disease.
  • No significant association was detected for any of the studied AKT1 haplotypes with Parkinson's disease.
  • The results did not replicate the protective effect of AKT1 variants reported in a previous Greek cohort.

Conclusions:

  • The findings do not support the hypothesis that genetic variants in AKT1 offer protection against Parkinson's disease in the studied Swedish population.
  • This replication study suggests that the previously identified protective AKT1 haplotype may not be a general factor in Parkinson's disease.
  • Further research may be needed to fully elucidate the role of AKT1 in Parkinson's disease pathogenesis.

More Related Videos

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...